These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults. Halperin SA; Arribas JR; Rupp R; Andrews CP; Chu L; Das R; Simon JK; Onorato MT; Liu K; Martin J; Helmond FA; J Infect Dis; 2017 Jun; 215(12):1789-1798. PubMed ID: 28549145 [TBL] [Abstract][Full Text] [Related]
4. Cellular and humoral immunity to Ebola Zaire glycoprotein and viral vector proteins following immunization with recombinant vesicular stomatitis virus-based Ebola vaccine (rVSVΔG-ZEBOV-GP). Raabe V; Lai L; Morales J; Xu Y; Rouphael N; Davey RT; Mulligan MJ Vaccine; 2023 Feb; 41(8):1513-1523. PubMed ID: 36725433 [TBL] [Abstract][Full Text] [Related]
5. Correlates of vaccine-induced protective immunity against Ebola virus disease. Medaglini D; Santoro F; Siegrist CA Semin Immunol; 2018 Oct; 39():65-72. PubMed ID: 30041831 [TBL] [Abstract][Full Text] [Related]
6. Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults. Halperin SA; Das R; Onorato MT; Liu K; Martin J; Grant-Klein RJ; Nichols R; Coller BA; Helmond FA; Simon JK; J Infect Dis; 2019 Aug; 220(7):1127-1135. PubMed ID: 31505665 [TBL] [Abstract][Full Text] [Related]
7. Baseline Asymptomatic Malaria Infection and Immunogenicity of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein. Mahon BE; Simon J; Widdowson MA; Samai M; Rogier E; Legardy-Williams J; Liu K; Schiffer J; Lange J; DeByle C; Pinner R; Schuchat A; Slutsker L; Goldstein S J Infect Dis; 2021 Dec; 224(11):1907-1915. PubMed ID: 34013349 [TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults. Lee AW; Liu K; Lhomme E; Blie J; McCullough J; Onorato MT; Connor L; Simon JK; Dubey S; VanRheenen S; Deutsch J; Owens A; Morgan A; Welebob C; Hyatt D; Nair S; Hamzé B; Guindo O; Sow SO; Beavogui AH; Leigh B; Samai M; Akoo P; Serry-Bangura A; Fleck S; Secka F; Lowe B; Watson-Jones D; Roy C; Hensley LE; Kieh M; Coller BG; Clin Infect Dis; 2024 Apr; 78(4):870-879. PubMed ID: 37967326 [TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study. Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP; Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591 [TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo. Hoff NA; Bratcher A; Kelly JD; Musene K; Kompany JP; Kabamba M; Mbala-Kingebeni P; Dighero-Kemp B; Kocher G; Elliott E; Reilly C; Halbrook M; Ilunga Kebela B; Gadoth A; Ngoie Mwamba G; Tambu M; McIlwain DR; Mukadi P; Hensley LE; Ahuka-Mundeke S; Rutherford GW; Muyembe-Tamfum JJ; Rimoin AW Proc Natl Acad Sci U S A; 2022 Feb; 119(6):. PubMed ID: 35110410 [TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials. Simon JK; Kennedy SB; Mahon BE; Dubey SA; Grant-Klein RJ; Liu K; Hartzel J; Coller BG; Welebob C; Hanson ME; Grais RF Vaccine; 2022 Nov; 40(46):6599-6606. PubMed ID: 36208978 [TBL] [Abstract][Full Text] [Related]
12. Serostatus cutoff levels and fold increase to define seroresponse to recombinant vesicular stomatitis virus - Zaire Ebola virus envelope glycoprotein vaccine: An evidence-based analysis. Antonello J; Grant-Klein RJ; Nichols R; Kennedy SB; Dubey S; Simon JK Vaccine; 2020 Jun; 38(31):4885-4891. PubMed ID: 32499064 [TBL] [Abstract][Full Text] [Related]
13. Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic. Coller BG; Blue J; Das R; Dubey S; Finelli L; Gupta S; Helmond F; Grant-Klein RJ; Liu K; Simon J; Troth S; VanRheenen S; Waterbury J; Wivel A; Wolf J; Heppner DG; Kemp T; Nichols R; Monath TP Vaccine; 2017 Aug; 35(35 Pt A):4465-4469. PubMed ID: 28647166 [TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial. Agnandji ST; Fernandes JF; Bache EB; Obiang Mba RM; Brosnahan JS; Kabwende L; Pitzinger P; Staarink P; Massinga-Loembe M; Krähling V; Biedenkopf N; Fehling SK; Strecker T; Clark DJ; Staines HM; Hooper JW; Silvera P; Moorthy V; Kieny MP; Adegnika AA; Grobusch MP; Becker S; Ramharter M; Mordmüller B; Lell B; ; Krishna S; Kremsner PG PLoS Med; 2017 Oct; 14(10):e1002402. PubMed ID: 28985239 [TBL] [Abstract][Full Text] [Related]
15. Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice. Konduru K; Bradfute SB; Jacques J; Manangeeswaran M; Nakamura S; Morshed S; Wood SC; Bavari S; Kaplan GG Vaccine; 2011 Apr; 29(16):2968-77. PubMed ID: 21329775 [TBL] [Abstract][Full Text] [Related]
16. Effects of Gamma Irradiation of Human Serum Samples from rVSVΔG-ZEBOV-GP (V920) Ebola Virus Vaccine Recipients on Plaque-Reduction Neutralization Assays. Grant-Klein RJ; Antonello J; Nichols R; Dubey S; Simon JK Am J Trop Med Hyg; 2021 Mar; 104(5):1751-1754. PubMed ID: 33782211 [TBL] [Abstract][Full Text] [Related]
17. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Marzi A; Engelmann F; Feldmann F; Haberthur K; Shupert WL; Brining D; Scott DP; Geisbert TW; Kawaoka Y; Katze MG; Feldmann H; Messaoudi I Proc Natl Acad Sci U S A; 2013 Jan; 110(5):1893-8. PubMed ID: 23319647 [TBL] [Abstract][Full Text] [Related]
18. Assessment of the ability of V920 recombinant vesicular stomatitis-Zaire ebolavirus vaccine to replicate in relevant arthropod cell cultures and vector species. Bergren NA; Miller MR; Monath TP; Kading RC Hum Vaccin Immunother; 2018 Apr; 14(4):994-1002. PubMed ID: 29206076 [TBL] [Abstract][Full Text] [Related]
19. Estimation of the correlates of protection of the rVSVΔG-ZEBOV-GP Zaire ebolavirus vaccine: a post-hoc analysis of data from phase 2/3 clinical trials. Grais RF; Kennedy SB; Mahon BE; Dubey SA; Grant-Klein RJ; Liu K; Hartzel J; Coller BA; Welebob C; Hanson ME; Simon JK Lancet Microbe; 2021 Feb; 2(2):e70-e78. PubMed ID: 35544244 [TBL] [Abstract][Full Text] [Related]
20. A Recombinant Vesicular Stomatitis Virus Ebola Vaccine. Regules JA; Beigel JH; Paolino KM; Voell J; Castellano AR; Hu Z; Muñoz P; Moon JE; Ruck RC; Bennett JW; Twomey PS; Gutiérrez RL; Remich SA; Hack HR; Wisniewski ML; Josleyn MD; Kwilas SA; Van Deusen N; Mbaya OT; Zhou Y; Stanley DA; Jing W; Smith KS; Shi M; Ledgerwood JE; Graham BS; Sullivan NJ; Jagodzinski LL; Peel SA; Alimonti JB; Hooper JW; Silvera PM; Martin BK; Monath TP; Ramsey WJ; Link CJ; Lane HC; Michael NL; Davey RT; Thomas SJ; N Engl J Med; 2017 Jan; 376(4):330-341. PubMed ID: 25830322 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]